309 related articles for article (PubMed ID: 22154077)
1. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors.
Starostina NG; Kipreos ET
Trends Cell Biol; 2012 Jan; 22(1):33-41. PubMed ID: 22154077
[TBL] [Abstract][Full Text] [Related]
2. Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Croucher DR; Rickwood D; Tactacan CM; Musgrove EA; Daly RJ
Mol Cell Biol; 2010 Nov; 30(21):5057-70. PubMed ID: 20805359
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors.
Lu Z; Hunter T
Cell Cycle; 2010 Jun; 9(12):2342-52. PubMed ID: 20519948
[TBL] [Abstract][Full Text] [Related]
4. CDK inhibitors, p21(Cip1) and p27(Kip1), participate in cell cycle exit of mammalian cardiomyocytes.
Tane S; Ikenishi A; Okayama H; Iwamoto N; Nakayama KI; Takeuchi T
Biochem Biophys Res Commun; 2014 Jan; 443(3):1105-9. PubMed ID: 24380855
[TBL] [Abstract][Full Text] [Related]
5. Development of mice without Cip/Kip CDK inhibitors.
Tateishi Y; Matsumoto A; Kanie T; Hara E; Nakayama K; Nakayama KI
Biochem Biophys Res Commun; 2012 Oct; 427(2):285-92. PubMed ID: 23000166
[TBL] [Abstract][Full Text] [Related]
6. Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KIP1, in rat hearts during development.
Koh KN; Kang MJ; Frith-Terhune A; Park SK; Kim I; Lee CO; Koh GY
J Mol Cell Cardiol; 1998 Mar; 30(3):463-74. PubMed ID: 9515024
[TBL] [Abstract][Full Text] [Related]
7. The multiple roles of the cyclin-dependent kinase inhibitory protein p57(KIP2) in cerebral cortical neurogenesis.
Tury A; Mairet-Coello G; DiCicco-Bloom E
Dev Neurobiol; 2012 Jun; 72(6):821-42. PubMed ID: 22076965
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase inhibitor p57Kip2 regulates cell cycle exit, differentiation, and migration of embryonic cerebral cortical precursors.
Tury A; Mairet-Coello G; DiCicco-Bloom E
Cereb Cortex; 2011 Aug; 21(8):1840-56. PubMed ID: 21245411
[TBL] [Abstract][Full Text] [Related]
9. Functional Versatility of the CDK Inhibitor p57
Creff J; Besson A
Front Cell Dev Biol; 2020; 8():584590. PubMed ID: 33117811
[TBL] [Abstract][Full Text] [Related]
10. The influence of high glucose on the Cip/Kip family expression profiles in HRECs.
Tian J; Ma H; Luo Y; Hu A; Lin S; Li T; Guo K; Li J; Cai M; Tang S
J Mol Histol; 2013 Dec; 44(6):705-13. PubMed ID: 23636608
[TBL] [Abstract][Full Text] [Related]
11. A cell-autonomous requirement for Cip/Kip cyclin-kinase inhibitors in regulating neuronal cell cycle exit but not differentiation in the developing spinal cord.
Gui H; Li S; Matise MP
Dev Biol; 2007 Jan; 301(1):14-26. PubMed ID: 17123502
[TBL] [Abstract][Full Text] [Related]
12. The activity and stability of the intrinsically disordered Cip/Kip protein family are regulated by non-receptor tyrosine kinases.
Huang Y; Yoon MK; Otieno S; Lelli M; Kriwacki RW
J Mol Biol; 2015 Jan; 427(2):371-386. PubMed ID: 25463440
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of p27
Whitcomb EA; Tsai YC; Basappa J; Liu K; Le Feuvre AK; Weissman AM; Taylor A
FASEB J; 2019 Jan; 33(1):1235-1247. PubMed ID: 30113882
[TBL] [Abstract][Full Text] [Related]
14. ZNF313 is a novel cell cycle activator with an E3 ligase activity inhibiting cellular senescence by destabilizing p21(WAF1.).
Han J; Kim YL; Lee KW; Her NG; Ha TK; Yoon S; Jeong SI; Lee JH; Kang MJ; Lee MG; Ryu BK; Baik JH; Chi SG
Cell Death Differ; 2013 Aug; 20(8):1055-67. PubMed ID: 23645206
[TBL] [Abstract][Full Text] [Related]
15. Mapping of CIP/KIP inhibitors, G1 cyclins D1, D3, E and p53 proteins in the rat term placenta.
Korgun ET; Unek G; Herrera E; Jones CJ; Wadsack C; Kipmen-Korgun D; Desoye G
Histochem Cell Biol; 2011 Sep; 136(3):267-78. PubMed ID: 21789682
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of cell cycle arrest and terminal differentiation in a maximally proliferative human epithelial tissue: Lessons from the human hair follicle matrix.
Purba TS; Brunken L; Peake M; Shahmalak A; Chaves A; Poblet E; Ceballos L; Gandarillas A; Paus R
Eur J Cell Biol; 2017 Sep; 96(6):632-641. PubMed ID: 28413121
[TBL] [Abstract][Full Text] [Related]
18. New functional activities for the p21 family of CDK inhibitors.
LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
[TBL] [Abstract][Full Text] [Related]
19. p57KIP2: "Kip"ing the cell under control.
Pateras IS; Apostolopoulou K; Niforou K; Kotsinas A; Gorgoulis VG
Mol Cancer Res; 2009 Dec; 7(12):1902-19. PubMed ID: 19934273
[TBL] [Abstract][Full Text] [Related]
20. CDK inhibitors: cell cycle regulators and beyond.
Besson A; Dowdy SF; Roberts JM
Dev Cell; 2008 Feb; 14(2):159-69. PubMed ID: 18267085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
